{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:13Z","timestamp":1792791073156,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"Importance<\/jats:title>Approximately 10% to 15% of ischemic strokes are associated with cancer; cancer-associated stroke, particularly when cryptogenic, is associated with high rates of recurrent stroke and major bleeding. Limited data exist on the safety and efficacy of different antithrombotic strategies in patients with cancer and cryptogenic stroke.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare apixaban vs aspirin for the prevention of adverse clinical outcomes in patients with history of cancer and cryptogenic stroke.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>Post hoc analysis of data from 1015 patients with a recent cryptogenic stroke and biomarker evidence of atrial cardiopathy in the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) trial, a multicenter, randomized, double-blind clinical trial conducted from 2018 to 2023 at 185 stroke centers in North America. Data analysis was performed from October 15, 2023, to May 23, 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily vs oral aspirin, 81 mg, once daily. Subgroups of patients with and without cancer at baseline were examined.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome for this post hoc analysis was a composite of major ischemic or major hemorrhagic events. Major ischemic events were recurrent ischemic stroke, myocardial infarction, systemic embolism, and symptomatic deep vein thrombosis or pulmonary embolism. Major hemorrhagic events included symptomatic intracranial hemorrhage and any major extracranial hemorrhage.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 1015 participants (median [IQR] age, 68 [60-76] years; 551 [54.3%] female), 137 (13.5%) had a history of cancer. The median (IQR) follow-up was 1.5 (0.6-2.5) years for patients with history of cancer and 1.5 (0.6-3.0) years for those without history of cancer. Participants with history of cancer, compared with those without history of cancer, had a higher risk of major ischemic or major hemorrhagic events (hazard ratio [HR], 1.73; 95% CI, 1.10-2.71). Among those with history of cancer, 8 of 61 participants (13.1%) randomized to apixaban and 16 of 76 participants (21.1%) randomized to aspirin had a major ischemic or major hemorrhagic event; however, the risk was not significantly different between groups (HR, 0.61; 95% CI, 0.26-1.43). Comparing participants randomized to apixaban vs aspirin among those with cancer, events included recurrent stroke (5 [8.2%] vs 9 [11.8%]), major ischemic events (7 [11.5%] vs 14 [18.4%]), and major hemorrhagic events (1 [1.6%] vs 2 [2.6%]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Among participants in the ARCADIA trial with history of cancer, the risk of major ischemic and hemorrhagic events did not differ significantly with apixaban compared with aspirin.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03192215<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaneurol.2024.2404","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:00:34Z","timestamp":1723474834000},"page":"958","source":"Crossref","is-referenced-by-count":29,"title":["Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke"],"prefix":"10.1001","volume":"81","author":[{"given":"Babak B.","family":"Navi","sequence":"first","affiliation":[{"name":"Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York"},{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cushman","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Vermont Larner College of Medicine, Burlington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott E.","family":"Kasner","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S. V.","family":"Elkind","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Tirschwell","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"W. T.","family":"Longstreth","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington, Seattle"},{"name":"Department of Epidemiology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Kronmal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morin","family":"Beyeler","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York"},{"name":"Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Elm","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Zweifler","sequence":"additional","affiliation":[{"name":"Ochsner Neuroscience Institute, Ochsner Health, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tarsia","sequence":"additional","affiliation":[{"name":"Ochsner Neuroscience Institute, Ochsner Health, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo W.","family":"Cereda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Bianco","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neurocenter of Southern Switzerland EOC, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Costamagna","sequence":"additional","affiliation":[{"name":"Stroke Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"Neurology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Michel","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph P.","family":"Broderick","sequence":"additional","affiliation":[{"name":"Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Gladstone","sequence":"additional","affiliation":[{"name":"Sunnybrook Research Institute, Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, and Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hooman","family":"Kamel","sequence":"additional","affiliation":[{"name":"Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York"},{"name":"Deputy Editor, JAMA Neurology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Streib","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"noi240047r1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ene.14037","article-title":"Cancer prevalence higher in stroke patients than in the general population: the Dutch String-of-Pearls Institute (PSI) stroke study.","volume":"27","author":"Wilbers","year":"2020","journal-title":"Eur J Neurol"},{"issue":"12","key":"noi240047r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106818","article-title":"Trends in age and sex-specific prevalence of cancer and cancer subtypes in acute ischemic stroke from 2007-2019.","volume":"31","author":"Otite","year":"2022","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"noi240047r3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1212\/WNL.0000000000000539","article-title":"Recurrent thromboembolic events after ischemic stroke in patients with cancer.","volume":"83","author":"Navi","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"noi240047r4","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1111\/jth.15779","article-title":"Ischemic stroke with cancer: hematologic and embolic biomarkers and clinical outcomes.","volume":"20","author":"Navi","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"3","key":"noi240047r5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1161\/STROKEAHA.120.032002","article-title":"Cancer and embolic stroke of undetermined source.","volume":"52","author":"Navi","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"noi240047r6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ana.26129","article-title":"Mechanisms of ischemic stroke in patients with cancer: a prospective study.","volume":"90","author":"Navi","year":"2021","journal-title":"Ann Neurol"},{"issue":"2","key":"noi240047r7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"17","key":"noi240047r8","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer.","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"noi240047r9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer.","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"noi240047r10","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1161\/STROKEAHA.111.615203","article-title":"Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review.","volume":"42","author":"Plummer","year":"2011","journal-title":"Stroke"},{"issue":"21","key":"noi240047r11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021375","article-title":"Distinction in prevalence of atherosclerotic embolic sources in cryptogenic stroke with cancer status.","volume":"10","author":"Kikuno","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"noi240047r12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11060-015-1768-3","article-title":"Diagnostic yield of echocardiography in cancer patients with ischemic stroke.","volume":"123","author":"Merkler","year":"2015","journal-title":"J Neurooncol"},{"key":"noi240047r13","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer.","volume":"133","author":"Kamphuisen","year":"2014","journal-title":"Thromb Res"},{"issue":"7","key":"noi240047r14","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"7","key":"noi240047r15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial.","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"issue":"4","key":"noi240047r16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct.","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"noi240047r17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/1747493018799981","article-title":"The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods.","volume":"14","author":"Kamel","year":"2019","journal-title":"Int J Stroke"},{"issue":"4","key":"noi240047r18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/rth2.12223","article-title":"The risk of arterial thromboembolic events after cancer diagnosis.","volume":"3","author":"Navi","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"noi240047r19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.24325","article-title":"Association between incident cancer and subsequent stroke.","volume":"77","author":"Navi","year":"2015","journal-title":"Ann Neurol"},{"issue":"19","key":"noi240047r20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029423","article-title":"Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England.","volume":"12","author":"Ajabnoor","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"noi240047r21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.thromres.2022.09.014","article-title":"Cancer and stroke: what do we know and where do we go?","volume":"219","author":"Lun","year":"2022","journal-title":"Thromb Res"},{"issue":"2","key":"noi240047r22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/ana.22050","article-title":"Coagulopathy and embolic signal in cancer patients with ischemic stroke.","volume":"68","author":"Seok","year":"2010","journal-title":"Ann Neurol"},{"issue":"1","key":"noi240047r23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.5853\/jos.2016.00570","article-title":"Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study.","volume":"19","author":"Lee","year":"2017","journal-title":"J Stroke"},{"issue":"5","key":"noi240047r24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.","volume":"27","author":"Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"issue":"3","key":"noi240047r25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial.","volume":"75","author":"Navi","year":"2018","journal-title":"JAMA Neurol"},{"key":"noi240047r26","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241239266","article-title":"Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: a randomized clinical trial of biomarker targets.","author":"Chung","year":"2024","journal-title":"Int J Stroke"},{"issue":"5","key":"noi240047r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2953","article-title":"Association of embolic sources with cause-specific functional outcomes among adults with cryptogenic stroke.","volume":"1","author":"Kiyuna","year":"2018","journal-title":"JAMA Netw Open"},{"key":"noi240047r28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/502089","article-title":"Comparison of enoxaparin and warfarin for secondary prevention of cancer-associated stroke.","volume":"2015","author":"Jang","year":"2015","journal-title":"J Oncol"},{"issue":"1","key":"noi240047r29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/jcm11010123","article-title":"The role of factor Xa-independent pathway and anticoagulant therapies in cancer-related stroke.","volume":"11","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"noi240047r30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism.","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"noi240047r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25283","article-title":"Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis.","volume":"6","author":"Riaz","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2822378\/jamaneurology_navi_2024_oi_240047_1725483546.32916.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:06:14Z","timestamp":1725894374000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2822378"}},"subtitle":["A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2024.2404","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}